Targeted radiation blasts prostate cancer before surgery in new trial
NCT ID NCT06798558
Summary
This study is testing whether giving a targeted radiation drug called Lu-177-PSMA-617 (Pluvicto) before surgery can shrink or eliminate high-risk prostate cancer. Men with a specific type of high-risk prostate cancer that shows up on a special PSMA scan will receive two doses of the drug, followed by surgery to remove the prostate. Researchers will check if the cancer is less advanced after the drug treatment and monitor safety for about two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
John Theurer Cancer Center at Hackensack University Medical Center
RECRUITINGHackensack, New Jersey, 07601, United States
Contact
-
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
NOT_YET_RECRUITINGWashington D.C., District of Columbia, 20057, United States
Contact
-
MedStar Washington Hospital Center
NOT_YET_RECRUITINGWashington D.C., District of Columbia, 20010, United States
Contact
Conditions
Explore the condition pages connected to this study.